AARTIPHARM

Aarti Pharmalabs Share Price

 

Stock is trading on High Volume

 

Invest in Aarti Pharmalabs with 2.84X leverage

Invest with MTF

Performance

  • Low
  • ₹736
  • High
  • ₹775
  • 52 Week Low
  • ₹568
  • 52 Week High
  • ₹971
  • Open Price₹736
  • Previous Close₹730
  • Volume1,463,398
  • 50 DMA₹756.11
  • 100 DMA₹781.30
  • 200 DMA₹781.29

Investment Returns

  • Over 1 Month + 5.11%
  • Over 3 Month -8.75%
  • Over 6 Month -16.56%
  • Over 1 Year + 15.39%

Smart Investing Starts Here Start SIP with Aarti Pharmalabs for Steady Growth!

Invest Now

Aarti Pharmalabs Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 28.8
  • PEG Ratio
  • 5.6
  • Market Cap Cr
  • 6,905
  • P/B Ratio
  • 3.4
  • Average True Range
  • 22.84
  • EPS
  • 26.45
  • Dividend Yield
  • 0.7
  • MACD Signal
  • -0.33
  • RSI
  • 54.84
  • MFI
  • 76.42

Aarti Pharmalabs Financials

Aarti Pharmalabs Technicals

EMA & SMA

Current Price
₹761.75
+ 31.4 (4.3%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹743.21
  • 50 Day
  • ₹756.11
  • 100 Day
  • ₹781.30
  • 200 Day
  • ₹781.29

Resistance and Support

757.65 Pivot Speed
  • R3 817.90
  • R2 796.45
  • R1 779.10
  • S1 740.30
  • S2 718.85
  • S3 701.50

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Aarti Pharmalabs Ltd. is a leading pharmaceutical company in India, specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. It caters to global markets, providing high-quality and innovative solutions for various therapeutic segments.

Aarti Pharmalabs has an operating revenue of Rs. 1,906.08 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 17% is great, ROE of 13% is good. The company has a reasonable debt to equity of 5%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 51 which is a POOR score indicating inconsistency in earnings, a RS Rating of 59 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 84 indicates it belongs to a poor industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Aarti Pharmalabs Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-09 Quarterly Results
2025-08-12 Quarterly Results
2025-05-10 Audited Results & Final Dividend
2025-02-05 Quarterly Results, Dividend & Others To consider other business matters. per share(40%)Interim Dividend
2024-10-28 Quarterly Results
Date Purpose Remarks
2025-09-15 FINAL Rs.2.50 per share(50%)Final Dividend
2025-02-14 INTERIM Rs.2.50 per share(50%)Interim Dividend
2024-07-31 FINAL Rs.1.00 per share(20%)Final Dividend
2024-02-19 INTERIM Rs.2.00 per share(40%)Interim Dividend
View Aarti Pharmalabs Dividend History Arrow

Aarti Pharmalabs F&O

Aarti Pharmalabs Shareholding Pattern

42.88%
0.79%
5.3%
8.02%
0%
35.39%
7.62%

About Aarti Pharmalabs

  • NSE Symbol
  • AARTIPHARM
  • BSE Symbol
  • 543748
  • Managing Director
  • Mr. Narendra J Salvi
  • ISIN
  • INE0LRU01027

Similar Stocks to Aarti Pharmalabs

Aarti Pharmalabs FAQs

Aarti Pharmalabs share price is ₹761 As on 11 January, 2026 | 05:47

The Market Cap of Aarti Pharmalabs is ₹6905.1 Cr As on 11 January, 2026 | 05:47

The P/E ratio of Aarti Pharmalabs is 28.8 As on 11 January, 2026 | 05:47

The PB ratio of Aarti Pharmalabs is 3.4 As on 11 January, 2026 | 05:47

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23